Laura Chico
Stock Analyst at Wedbush
(2.26)
# 2,647
Out of 4,893 analysts
227
Total ratings
37.25%
Success rate
-1.06%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Initiates: Outperform | $17 | $15.21 | +11.77% | 1 | Jul 8, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $16 → $18 | $8.94 | +101.34% | 1 | Jun 30, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $17 → $15 | $3.46 | +333.53% | 2 | Jun 24, 2025 | |
| LEN Lennar | Reiterates: Neutral | $130 | $117.28 | +10.85% | 1 | Jun 18, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $121 | $134.46 | -10.01% | 18 | Jun 12, 2025 | |
| PHVS Pharvaris | Reiterates: Outperform | $27 | $19.15 | +41.03% | 6 | Jun 5, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Neutral | $13 → $8 | $8.04 | -0.44% | 11 | May 22, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $30 | $16.40 | +82.93% | 11 | May 16, 2025 | |
| GOSS Gossamer Bio | Reiterates: Outperform | $4 | $1.35 | +196.30% | 5 | May 16, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $18 → $17 | $5.37 | +216.57% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $10.39 | +63.62% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $2.63 | +52.09% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $15.28 | +96.34% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $24.37 | +6.69% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $50.13 | -44.15% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $13.81 | +211.37% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $17.69 | +143.14% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $0.42 | +613.44% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $20.76 | +73.41% | 6 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $6.75 | +314.81% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $19.40 | +49.48% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 | $9.20 | -34.78% | 9 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $147 | $135.26 | +8.68% | 9 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 → $48 | $30.82 | +55.74% | 12 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $12 | $1.26 | +856.18% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $33.03 | +48.35% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.56 | +96.63% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.65 | +136.81% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $17.12 | +145.33% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $12.07 | +40.85% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.41 | +2,566.02% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $3.99 | +25.31% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $58.92 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $2.55 | +96.08% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $14.85 | +900.00% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $8.32 | +8,557.28% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $51.53 | +443.37% | 1 | Apr 21, 2017 |
Maze Therapeutics
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $15.21
Upside: +11.77%
BioCryst Pharmaceuticals
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.94
Upside: +101.34%
Larimar Therapeutics
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $3.46
Upside: +333.53%
Lennar
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $117.28
Upside: +10.85%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $134.46
Upside: -10.01%
Pharvaris
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $19.15
Upside: +41.03%
Vigil Neuroscience
May 22, 2025
Downgrades: Neutral
Price Target: $13 → $8
Current: $8.04
Upside: -0.44%
Travere Therapeutics
May 16, 2025
Reiterates: Outperform
Price Target: $30
Current: $16.40
Upside: +82.93%
Gossamer Bio
May 16, 2025
Reiterates: Outperform
Price Target: $4
Current: $1.35
Upside: +196.30%
Solid Biosciences
May 16, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $5.37
Upside: +216.57%
May 15, 2025
Reiterates: Outperform
Price Target: $17
Current: $10.39
Upside: +63.62%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $2.63
Upside: +52.09%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $15.28
Upside: +96.34%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $24.37
Upside: +6.69%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $50.13
Upside: -44.15%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $13.81
Upside: +211.37%
Mar 14, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $17.69
Upside: +143.14%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $0.42
Upside: +613.44%
Mar 12, 2025
Reiterates: Outperform
Price Target: $36
Current: $20.76
Upside: +73.41%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $6.75
Upside: +314.81%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $19.40
Upside: +49.48%
Feb 12, 2025
Reiterates: Neutral
Price Target: $6
Current: $9.20
Upside: -34.78%
Feb 7, 2025
Maintains: Outperform
Price Target: $157 → $147
Current: $135.26
Upside: +8.68%
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $30.82
Upside: +55.74%
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $1.26
Upside: +856.18%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $33.03
Upside: +48.35%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.56
Upside: +96.63%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.65
Upside: +136.81%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $17.12
Upside: +145.33%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $12.07
Upside: +40.85%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.41
Upside: +2,566.02%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.99
Upside: +25.31%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $58.92
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.55
Upside: +96.08%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $14.85
Upside: +900.00%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $8.32
Upside: +8,557.28%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $51.53
Upside: +443.37%